about
Increasing antipsychotic dose for non response in schizophreniaIncreasing antipsychotic dose versus switching antipsychotic for non response in schizophreniaSwitching antipsychotic for non response in schizophreniaEfficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisAssessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.Regulation of synaptic plasticity in a schizophrenia model.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.Symptom control and patient adherence to treatment: key goals in the treatment of psychosis.Altered functional connectivity links in neuroleptic-naïve and neuroleptic-treated patients with schizophrenia, and their relation to symptoms including volition.Pharmacogenomics and schizophrenia: clinical implications.Cognitive Behavioral Therapy for Psychosis - Training Practices and Dissemination in the United States.Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.Weight gain and new onset diabetes associated with olanzapine and risperidone.Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisThird generation antipsychotic drugs: partial agonism or receptor functional selectivity?Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia.Treatments for chronic psychosis.Influence of CYP2D6 polymorphisms on symptomatology and side-effects of patients with schizophrenia in MalaysiaTargeted pharmacogenetic analysis of antipsychotic response in the CATIE study.Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature.Are second generation antipsychotics a distinct class?A systematic method for estimating individual responses to treatment with antipsychotics in CATIE.Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study.Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program.Treating schizophrenia now and developing strategies for the next decade.Pharmacologic treatment of schizophrenia: what the future holds.Development of Risperidone PLGA Microspheres.D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients.Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial.Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol.Naturalistic impact of second-generation antipsychotics on weight gain.The effects of switching from oral to LAI antipsychotic treatment on subjective experience of schizophrenic and schizoaffective patients: Preliminary results.Global assessment of psychosocial functioning and predictors of outcome in schizophrenia.Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients.
P2860
Q24186768-83238084-1FBB-4E1A-AC2C-3C6A7732938EQ24186772-0E6BB2B7-489D-40E7-BC90-34BC2A480E2DQ24187478-60316EB4-FF6B-4915-B029-DFA1E3A0273EQ24606868-BA6898D0-65E0-4891-BE80-6691A7BA9D7FQ33899442-57E2F390-E8DA-4E7B-852C-F4E3D61812D9Q33926334-AB47512A-A37F-4C5D-8C19-52018D795B0CQ33948009-D7E3D8A4-A9CF-4121-B7E3-9CCE2BE0AD21Q34338202-D8D98CE8-A3D0-4F1E-9BEA-D3F9854A8B46Q34450843-E2EE6BEE-4304-4985-B21F-EE661C462BA1Q34484352-3EF4F66A-50B4-4D56-A46F-52E04827382FQ34575636-00BE6CDE-5693-4957-A291-82E85DE010A2Q34657151-E9841856-A89A-4198-90A0-88DFF55E8734Q34661875-4DAD4B43-D4CD-4D2E-BD69-EA833F9216FAQ34733828-B7FF7BDF-3864-4ADF-BD96-299AA56896DEQ34982167-7DF8E976-B590-49B1-815B-8795FBA50C2DQ35012574-C9FD6723-8267-498A-A8C2-4DB863AA506EQ35143555-ECC29E56-F603-4A54-B3C0-5730118A3A71Q35236418-4D1B29A8-4B1D-499C-81F4-27ED14152E82Q35896386-FD3915CC-2229-460B-BA31-EAB071DE98B0Q36456196-CDB56473-E253-432B-BCBA-EC61F7322AACQ36720733-DB58DD75-92BC-4718-B53B-8496D1D80EE1Q36784527-BE8F81ED-5431-4E66-88B5-4FA59659BA26Q37120211-7E8B11DD-589D-41FF-B934-A84F2FB29091Q37124952-7C3F5941-8FA0-48CF-B3F9-60C1D48D7C62Q37760926-4E08BEBC-AED8-4482-8358-1DBEA11320E8Q39038512-289E6E77-FF77-43F7-AD2B-0522C8B65DE4Q40489428-0216F877-0FF9-4D54-9853-2DFE197DCE11Q40489435-FFDF243E-9E1F-4937-9CE6-EF8EE0C6A184Q41962765-C62E4134-6943-42FF-A12B-4B08DC0E78B6Q42056580-BD06E6ED-FB9C-44CA-8AC6-0B4A51B9A1B9Q42733571-6AC6B832-9F58-46BB-BBB9-FE1EAB6F7604Q43270061-24E33DA6-A7B8-4B30-81B8-8FD5A01153ECQ45029914-E2E5B25D-AEBF-40F6-8AE8-53EDA0B7D4C9Q47344131-A2E91468-9E1F-4DDB-99F5-E28A2424C0E4Q48059462-C6AA3124-E69F-4DD0-97EA-6AC087325180Q50778334-BA4965F2-CE08-4B3F-BE0A-7858844CD645Q53429141-73AA5383-D10F-41EE-9050-3CB7B938DFA6
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pharmacologic treatment of schizophrenia.
@ast
Pharmacologic treatment of schizophrenia.
@en
type
label
Pharmacologic treatment of schizophrenia.
@ast
Pharmacologic treatment of schizophrenia.
@en
prefLabel
Pharmacologic treatment of schizophrenia.
@ast
Pharmacologic treatment of schizophrenia.
@en
P1476
Pharmacologic treatment of schizophrenia.
@en
P2093
P304
P356
10.1016/S0006-3223(99)00059-1
P407
P577
1999-11-01T00:00:00Z